Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women - An Asian population-based study

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Hsieh, Kun Pin ^a,b   Chen, Li Chia ^c   Cheung, Kwok Leung ^c   Chang, Chao Sung ^a   Yang, Yi Hsin ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN; HORMONE;

ADJUVANT CHEMOTHERAPY; ADULT; AGE DISTRIBUTION; ARTICLE; ASIAN; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PATIENT COMPLIANCE; POPULATION RESEARCH; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT DURATION; AGE; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; KAPLAN MEIER METHOD; MEDICATION COMPLIANCE; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; TAIWAN;

AGE FACTORS; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HORMONES; HUMANS; KAPLAN-MEIER ESTIMATE; MEDICATION ADHERENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TAIWAN; TAMOXIFEN;

EID: 84896765788     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087027     Document Type: Article

References (21)

1. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907.
2. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, et al. (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23: 619-629. (Pubitemid 46224240)
3. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
4. Ruddy KJ, Partridge AH (2009) Adherence with adjuvant hormonal therapy for breast cancer. Ann Oncol 20: 401-402.
5. Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71: 1-9.
6. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109: 832-839. (Pubitemid 46333524)
7. McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, et al. (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99: 1763-1768.
8. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, et al. (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126: 529-537.
9. Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK (2011) Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130: 681-689.
10. Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, et al. (2010) Is breast cancer the same disease in Asian and Western countries? World J Surg 34: 2308-2324.
11. Bureau of Health Promotion (2012) Cancer Registry Annual Report 2009. Taipei, Taiwan: Department of Health, Exceutive Yuan.
12. Taiwan Bureau of National Health Insurance Insurance Coverage. Avariable: http://www.nhi.gov.tw/English/webdata/webdata.aspx?menu=11&menu-id= 296&webdata-id=1942&WD-ID=296 Accessed 20 April 2013.
13. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, et al. (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26: 556-562. (Pubitemid 351264348)
14. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, et al. (2004) New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 57: 1288-1294. (Pubitemid 40023149)
15. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108: 1515-1524.
16. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134: 459-478.
17. NCCN (2012) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Breast Cancer Version 3.
18. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618.
19. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14: 2738-2746. (Pubitemid 26329660)
20. Swedish Breast Cancer Cooperative G (1996) Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88: 1543-1549.
21. Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS (2006) Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 44: 471-477. (Pubitemid 43755427)